Lilly bolsters atopic dermatitis arsenal via $1.1B Dermira deal, gaining Dupixent challenger

Via its $1.1 billion takeout of Dermira on Friday, Eli Lilly added to its late-stage pipeline an atopic dermatitis therapy that could challenge Dupixent.

The price -- $18.75 per share -- is a premium of only 2% to Thursday’s close of $18.34, but the deal comes during a

Read the full 471 word article

User Sign In